---
layout: post
title: New Drug Approvals 2014 - Pt. XIII - Apremilast (Otezla™) (WIP)
date: '2014-11-12T17:22:00.000Z'
author: J Bach Hardie
tags: 
modified_time: '2014-11-12T17:22:12.877Z'
thumbnail: http://4.bp.blogspot.com/-Nmq0SnLoPM4/VD6dRR4DvlI/AAAAAAAAAcE/gYcvi8D3PQ4/s72-c/1-s2.0-S0006295212000263-gr1.jpg
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-5987358988751684669
blogger_orig_url: https://www.blogger.com/comment.g?blogID=2546008714740235720&postID=5987358988751684669
---

<div class="separator" style="clear: both; text-align: center;">
<a href="http://mms.businesswire.com/media/20140324006359/en/408377/5/Otezla-30mg_single.jpg?download=1" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://mms.businesswire.com/media/20140324006359/en/408377/5/Otezla-30mg_single.jpg?download=1" height="400" width="317" /></a></div>
<br />
<br />
On March 21st the <a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm390091.htm" target="_blank">FDA Approved</a> <a href="http://en.wikipedia.org/wiki/Apremilast" target="_blank">Apremilast</a> (trade name Otezla™) for the treatment of psoriatic arthritis in adults. Psoriatic arthritis is a type of inflammatory arthritis that is associated with skin psoriasis. The disease mechanism is still unknown, and it is diagnosed primarily through its association with skin psoriasis and through ruling out rheumatoid arthritis. Symptoms focus around painful and/or inflamed joints and extreme exhaustion. Early treatment of inflammation is crucial, since prolonged inflammation at the joints can cause permanent damage.<br />
<br />
<b>Chemical identity</b><br />
<br />
<b>&nbsp;</b><b>IUPAC Name: </b><span style="word-wrap: break-word;">N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]acetamide</span><b>&nbsp;</b><br />
<b>InChI: </b><span style="word-wrap: break-word;">InChI=1S/C22H24N2O7S/c1-5-31-19-11-14(9-10-18(19)30-3)17(12-32(4,28)29)24-21(26)15-7-6-8-16(23-13(2)25)20(15)22(24)27/h6-11,17H,5,12H2,1-4H3,(H,23,25)/t17-/m1/s1</span><b>&nbsp;</b><br />
<b>InChIKey: </b><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pccompound&amp;term=%22IMOZEMNVLZVGJZ-QGZVFWFLSA-N%22[InChIKey]" name="inchikey2entrez"><span style="word-wrap: break-word;">IMOZEMNVLZVGJZ-QGZVFWFLSA-N</span></a><b>&nbsp;</b><br />
<b>Canonical SMILES : </b><span style="word-wrap: break-word;">CCOC1=C(C=CC(=C1)C(CS(=O(=O)C)N2C(=O)C3=C(C2=O)C(=CC=C3)NC(=O)C)OC</span><b>&nbsp;</b><br />
<b>Isomeric SMILES: </b><span style="word-wrap: break-word;">CCOC1=C(C=CC(=C1)[C@@H](CS(=O(=O)C)N2C(=O)C3=C(C2=O)C(=CC=C3)NC(=O)C)OC</span><br />
<br />
<b>Mechanism of action</b> <br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="http://4.bp.blogspot.com/-Nmq0SnLoPM4/VD6dRR4DvlI/AAAAAAAAAcE/gYcvi8D3PQ4/s1600/1-s2.0-S0006295212000263-gr1.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://4.bp.blogspot.com/-Nmq0SnLoPM4/VD6dRR4DvlI/AAAAAAAAAcE/gYcvi8D3PQ4/s1600/1-s2.0-S0006295212000263-gr1.jpg" height="385" width="640" /></a></div>
<div style="text-align: center;">
<span style="font-size: xx-small;">Apremilast's action on the cytokine production pathway (<a href="http://dx.doi.org/10.1016%2Fj.bcp.2012.01.001" target="_blank">Schafer 2012</a>)</span></div>
<br />
<br />
Apremilast is a thalidomide derivative, but has a different mechanism of action from thalidomide and other drugs in that family. Apremilast acts by inhibiting proteins of the phosphodiesterase-4 (PDE4) family. PDE4 enzymes are involved in regulating intracellular pathways in epithelial, immune, and central nervous system cells through the hydrolisis of cAMP to AMP. Inhibition of PDE4 leads to higher levels of intracellular cAMP, which in turn blocks the production of pro-inflammatory cytokines, such as TNF-α, IFN-γ, and IL-2 from peripheral blood monocytes and T cells, and increases the production of anti-inflammatory mediators, such as IL-10.<br />
<br />
<b>Clinical trials</b><br />
<b><br /></b>
The Psoriatic Arthritis Long-term Assessment of Clinical Efficacy 1 (PALACE 1) compared apremilast with placebo in patients with active psoriatic arthritis despite prior traditional disease-modifying antirheumatic drug (DMARD) and/or biologic therapy.&nbsp;After 16 weeks of treatment, significantly more apremilast 20 mg BID (31%) and 30 mg BID (40%) patients achieved at least a 20% improvement in the <a href="http://www.ncbi.nlm.nih.gov/pubmed/7779114?dopt=Abstract" target="_blank">American College of Rheumatology (ACR) criteria</a> versus placebo (19%) (p&lt;0.001). The main side effects reported